Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MBX Biosciences, Inc. Common Stock (MBX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: MBX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 676.25M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 220608 | Beta - | 52 Weeks Range 7.25 - 27.50 | Updated Date 03/27/2025 |
52 Weeks Range 7.25 - 27.50 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.48 |
Earnings Date
Report Date 2025-03-17 | When - | Estimate - | Actual -0.4663 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 613914658 | Price to Sales(TTM) - |
Enterprise Value 613914658 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 31853700 | Shares Floating 14361705 |
Shares Outstanding 31853700 | Shares Floating 14361705 | ||
Percent Insiders 3.08 | Percent Institutions 54.94 |
Analyst Ratings
Rating 4.75 | Target Price - | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
MBX Biosciences, Inc. Common Stock
Company Overview
History and Background
MBX Biosciences is a biopharmaceutical company focused on developing peptide therapeutics to treat endocrine diseases. Founded to address unmet needs in endocrine care, the company aims to create innovative solutions for patients with rare and prevalent disorders. The company has secured significant funding and advanced its pipeline of product candidates through preclinical and clinical development.
Core Business Areas
- Endocrine Therapeutics Development: Focuses on creating and advancing a pipeline of peptide therapeutics targeting endocrine diseases. This includes research, preclinical studies, clinical trials, and regulatory activities.
Leadership and Structure
MBX Biosciences has a leadership team comprised of experienced individuals in drug development, endocrinology, and business management. Specific leadership details, including names and titles, would require consulting the company's website or recent press releases. The organizational structure consists of research, development, clinical, and administrative teams.
Top Products and Market Share
Key Offerings
- MBX 214: An investigational long-acting parathyroid hormone (PTH) analog being developed for hypoparathyroidism. Currently in clinical trials. Market share is not yet applicable as the product is not commercialized. Competitors include Ascendis Pharma (TransCon PTH), and Takeda (Natpara, though currently unavailable).
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on endocrine disorders, is characterized by high R&D costs, lengthy regulatory approval processes, and significant market potential for innovative therapies. Demand for effective treatments for endocrine diseases such as hypoparathyroidism and obesity is growing.
Positioning
MBX Biosciences is positioned as a company developing innovative peptide therapeutics for endocrine diseases. Its competitive advantage lies in its proprietary peptide engineering platform and focus on creating long-acting analogs with improved efficacy and safety profiles.
Total Addressable Market (TAM)
The TAM for hypoparathyroidism is estimated to be in the billions of dollars, driven by the high unmet need for effective and convenient treatments. MBX Biosciences is positioned to capture a significant share of this market with successful development and commercialization of MBX 214 and other pipeline products.
Upturn SWOT Analysis
Strengths
- Proprietary peptide engineering platform
- Experienced leadership team
- Strong focus on endocrine diseases
- Pipeline of novel therapeutic candidates
Weaknesses
- Reliance on clinical trial success
- Limited commercial infrastructure
- Potential for competition from established pharmaceutical companies
- Dependence on securing funding for research and development
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to address other endocrine diseases
- Positive clinical trial results for MBX 214
- Advancements in peptide drug delivery technologies
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from existing and emerging therapies
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- Ascendis Pharma (ASND)
- Takeda Pharmaceutical Company Limited (TAK)
Competitive Landscape
MBX Biosciences faces competition from established pharmaceutical companies and other biotechnology firms developing treatments for endocrine diseases. Its competitive advantage lies in its innovative peptide engineering platform and focus on developing long-acting analogs with improved efficacy and safety profiles. *Note: Market shares are illustrative and do not reflect actual values for MBX Biosciences*.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth information is not publicly available due to the company's private status. Growth is dependent on successful clinical trial outcomes and future funding rounds.
Future Projections: Future projections depend on successful clinical development of MBX 214 and other pipeline assets. Analyst estimates are not publicly available.
Recent Initiatives: Recent initiatives include advancing MBX 214 through clinical trials and expanding the pipeline with new peptide therapeutic candidates.
Summary
MBX Biosciences is a biopharmaceutical company focusing on endocrine diseases, with a promising pipeline led by MBX 214. As a private company, detailed financial information is unavailable, but the company's success hinges on clinical trial outcomes and securing further funding. Its proprietary peptide engineering platform and focus on long-acting analogs position it competitively in the market. Key risks include clinical trial failures and competition from larger pharmaceutical companies, but the potential market for hypoparathyroidism treatments is significant.
Similar Companies
- ASND
- TAK
- Lilly (LLY)
Sources and Disclaimers
Data Sources:
- Company website
- Press releases
- Industry reports
- Analyst reports (where available)
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Market share data is estimated and may not be precise. Financial data for private companies are not comprehensive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MBX Biosciences, Inc. Common Stock
Exchange NASDAQ | Headquaters Carmel, IN, United States | ||
IPO Launch date 2024-09-13 | CEO, President & Director Mr. Peter Kent Hawryluk MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://mbxbio.com |
Full time employees 43 | Website https://mbxbio.com | ||
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.